New Zealand markets closed

Precision BioSciences, Inc. (DTIL)

NasdaqCM - NasdaqCM Real-time price. Currency in USD
Add to watchlist
9.88-0.05 (-0.50%)
At close: 04:00PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close9.93
Open10.00
Bid0.00 x 0
Ask0.00 x 0
Day's range9.59 - 10.16
52-week range8.25 - 20.25
Volume10,391
Avg. volume40,004
Market cap68.425M
Beta (5Y monthly)1.73
PE ratio (TTM)N/A
EPS (TTM)-5.61
Earnings date02 Aug 2024 - 06 Aug 2024
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est33.00
  • Business Wire

    Precision BioSciences to Present at the Upcoming JonesTrading Healthcare Seaside Summit

    DURHAM, N.C., July 08, 2024--Precision BioSciences, Inc. (Nasdaq: DTIL), an advanced gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies, today announced that the company will present at the upcoming JonesTrading Healthcare Seaside Summit being held July 14-16, 2024 in San Diego, California.

  • Business Wire

    Precision BioSciences Announces its Addition to the Russell Microcap® Index

    DURHAM, N.C., July 01, 2024--Precision BioSciences, Inc. (Nasdaq: DTIL), an advanced gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for sophisticated gene edits, including gene elimination, insertion, and excision, today announced its addition to the Russell Microcap® Index. Precision’s inclusion in the index follows the conclusion of the 2024 Russell indexes annual reconstitution, which became effective after the close of U.S. mark

  • Business Wire

    Precision BioSciences Announces Presentation at UMDF Mitochondrial Medicine 2024 Supporting Advancement of PBGENE-PMM Program Towards IND and/or CTA in 2025

    DURHAM, N.C., June 27, 2024--Precision BioSciences, Inc. (Nasdaq: DTIL), an advanced gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for sophisticated gene edits, including gene elimination, insertion, and excision, is presenting data today at the United Mitochondrial Disease Foundation’s (UMDF) Mitochondrial Medicine 2024 Conference being held in Cleveland, Ohio from June 26-29, 2024.